Stemcells Inc (STEM) 1.54 $STEM Technical Round
Post# of 273258
Posted On: 09/02/2016 5:22:45 PM
Stemcells Inc (STEM) 1.54 $STEM
Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 3.05 (+0.02), STEM: 1.54 (unch), PETX: 8.81 (-0.11), THLD: 1.21 (+0.16)
Markets-At-A-Glance
AP - Tue Aug 16, 10:36PM CDT
NEW YORK (AP) — A snapshot of major stock and commodities market indicators Tuesday:
STEM: 1.54 (unch)
StemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger
GlobeNewswire - Tue Aug 16, 8:14AM CDT
StemCells, Inc. (NASDAQ:STEM) and Microbot Medical Ltd., a private company organized under the laws of the State of Israel ("Microbot"
, today announced that they have entered into a definitive merger agreement, with plans to pursue the development of robotics based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions.
STEM: 1.54 (unch)
StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data
GlobeNewswire - Tue May 31, 7:15AM CDT
StemCells, Inc. (NASDAQ:STEM) (the "Company" today announced its decision to terminate the Company's Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study's Interim Analysis Data Monitoring Committee (the "IA-DMC" . While the results showed overall improvement in patients treated with the Company's proprietary cells, the magnitude of the effect and the perceived trend of the effect over time did not justify continuing the study or exploring the variability in the initial patient observations, given the financial resources available to the Company.
STEM: 1.54 (unch)
StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study
GlobeNewswire - Tue May 10, 9:00AM CDT
StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway(TM) Study later this month as part of the Company's first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June.
STEM: 1.54 (unch)
StemCells, Inc. Announces 1-for-12 Reverse Stock Split
GlobeNewswire - Fri May 06, 11:49AM CDT
StemCells, Inc. (NASDAQ:STEM), announced today that at its annual stockholders meeting held on May 5, 2016, the Company's stockholders voted to approve a reverse stock split of the Company's common stock at a ratio of 1-for-12. Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Monday, May 9, 2016, under the existing trading symbol "STEM" and a new CUSIP number 85857R 303.
STEM: 1.54 (unch)
StemCells, Inc. (NASDAQ: STEM) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 6:45AM CDT
PALO ALTO, CA / ACCESSWIRE / May 3, 2016 / StemCells, Inc. (NASDAQ: STEM) a company engaged in the research, development, and commercialization of stem cell therapeutics, recently announced that management will make a presentation on the Company's programs, pipeline and operations at the 3rd Annual Growth Capital Expo MicroCap Investor Conference, held May 3 - 5, 2016 at Caesars Palace in Las Vegas, NV. The Company will be presenting at 11:00 a.m. Pacific Daylight Time on Wednesday, May 4. A live webcast of the presentation will be available through the Company's corporate website: http://www.stemcellsinc.com. Interested parties are encouraged to connect to the website at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary.
STEM: 1.54 (unch)
StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV
GlobeNewswire - Wed Apr 27, 7:05AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 3rd Annual Growth Capital Expo MicroCap Investor Conference, held May 3 - 5, 2016 at Caesars Palace in Las Vegas, NV. The Company will be presenting at 11:00 a.m. Pacific Daylight Time on Wednesday, May 4.
STEM: 1.54 (unch)
Top Penny Stocks: Four Trending Small Cap Stocks That Require Your Attention on April 18th 2016
ACCESSWIRE - Mon Apr 18, 10:17AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. SKLN, STEM, CYTX, and TRTC have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
SKLN: 0.18 (+0.02), CYTX: 2.05 (unch), STEM: 1.54 (unch)
StemCells, Inc. Presents Interim Results from its Phase II Pathway Study in Chronic Cervical Spinal Cord Injury at ASIA Annual Meeting
GlobeNewswire - Mon Apr 18, 7:05AM CDT
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, announced today that Dr. Stephen Huhn, the Company's Chief Medical Officer and VP of Clinical Research, presented additional details on its ongoing Phase II Pathway(TM) Study of HuCNS-SC cells for the treatment of chronic cervical spinal cord injuries. The presentation, which took place at the 2016 American Spinal Injury Association (ASIA) annual meeting in Philadelphia on Friday, April 15, included a top line update for the six patients enrolled in open label Cohort I from the Pathway Study. The 6-month results from Cohort I showed that muscle strength had improved in five of the six patients with four of these five patients also demonstrating improved performance on functional tasks assessing dexterity and fine motor skills. In addition, four of the six patients had improvement in the level of cord injury as measured by ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) assessment. The Company expects to release detailed final 12-month results on this first open-label cohort later this quarter.
STEM: 1.54 (unch)
StemCells, Inc., Pathway(TM) Study in Cervical Spinal Cord Injury Featured in The Downey Patriot
GlobeNewswire - Wed Mar 30, 3:13PM CDT
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced the company's ongoing Phase II Pathway(TM) Study in cervical spinal cord injury (SCI) was featured in an article published in The Downey Patriot.
STEM: 1.54 (unch)
Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Feb 04, 3:07PM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3 Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Communications. Other panel members will include Adi Mohanty, Co-CEO, BioTime, Karine Kleinhaus, Div. VP, N.A., Pluristem Therapeutics, Dan Goldberger, CEO, Xtant Medical, and Mark Hedrick, MD, CEO, Cytori Therapeutics.
PSTI: 1.65 (+0.01), STEM: 1.54 (unch)
Endonovo Therapeutics Tops Our List For Investor Potential in Biotechs
ACCESSWIRE - Thu Jan 28, 11:11AM CST
LAS VEGAS, NV / ACCESSWIRE / January 28, 2016 / Now that investors have gotten their first taste of the potential returns from the treatment of liver diseases, such as hepatitis C, which generated over $12.5 billion in 2014 sales and another $14.3 billion in the first nine months of 2015 for Gilead, companies are now looking to target other large liver disease markets.
INO: 9.08 (-0.06), PSTI: 1.65 (+0.01), GERN: 2.75 (+0.02), STEM: 1.54 (unch)
CORRECTING and REPLACING -- StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Jan 28, 10:15AM CST
In a release issued under the same headline earlier today by StemCells, Inc. (Nasdaq:STEM), please note that in the third paragraph of the release, the 2016 Disruptive Growth and Healthcare Conference date should be Feb. 10, not Feb. 18 as previously stated. The corrected release follows:
STEM: 1.54 (unch)
StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Jan 28, 7:05AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that management will make presentations on the Company's programs, pipeline and operations at two upcoming conferences in February.
STEM: 1.54 (unch)
3 Stocks Tackling Concussion Issues in Pro Athletes
ACCESSWIRE - Wed Jan 20, 7:45AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / The 2015 drama Concussion starring Will Smith follows the story of Dr. Bennet Omalu's battle with the National Football League to acknowledge research on the brain damage suffered by professional football players. After examining the brains of many deceased NFL players, Dr. Omalu coined the term chronic traumatic encephalopathy (CTE) to represent the large accumulation of tau protein on the brain causing a wide range of mental problems.
STEM: 1.54 (unch), CEMI: 7.22 (+0.05), CUR: 0.25 (-0.02)
StemCells, Inc. CEO Martin McGlynn Passes Baton to President and COO Ian Massey
GlobeNewswire - Mon Jan 11, 7:05AM CST
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced that Dr. Ian Massey, its President and Chief Operating Officer, has been appointed by the Board of Directors to succeed Martin McGlynn as the Company's Chief Executive Officer, effective January 18, 2016. Massey has additionally been elected to the Board.
STEM: 1.54 (unch)
StemCells, Inc. to Participate at the 8th Annual Biotech Showcase Investor Conference
GlobeNewswire - Wed Jan 06, 7:05AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 8 Annual Biotech Showcase Investor Conference. Management is scheduled to speak at 4:30 p.m. Pacific Standard Time on Monday, January 11, at the Parc 55 Hotel, located at 55 Cyril Magnin Street, San Francisco.
STEM: 1.54 (unch)
StemCells, Inc. Announces Strategic Realignment
GlobeNewswire - Wed Dec 23, 7:05AM CST
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced a strategic realignment to fully focus the Company's resources on its proprietary HuCNS-SC platform technology for the treatment of chronic spinal cord injury (SCI).
STEM: 1.54 (unch)
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Tue Dec 08, 8:02AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird" in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.
STEM: 1.54 (unch)
Technical Roundup on Biotech Stocks -- Anavex Life Sciences, Threshold Pharma, StemCells, and Aratana Therapeutics
PR Newswire - Wed Aug 17, 7:17AM CDT
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
AVXL: 3.05 (+0.02), STEM: 1.54 (unch), PETX: 8.81 (-0.11), THLD: 1.21 (+0.16)
Markets-At-A-Glance
AP - Tue Aug 16, 10:36PM CDT
NEW YORK (AP) — A snapshot of major stock and commodities market indicators Tuesday:
STEM: 1.54 (unch)
StemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger
GlobeNewswire - Tue Aug 16, 8:14AM CDT
StemCells, Inc. (NASDAQ:STEM) and Microbot Medical Ltd., a private company organized under the laws of the State of Israel ("Microbot"
, today announced that they have entered into a definitive merger agreement, with plans to pursue the development of robotics based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions. STEM: 1.54 (unch)
StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data
GlobeNewswire - Tue May 31, 7:15AM CDT
StemCells, Inc. (NASDAQ:STEM) (the "Company"
today announced its decision to terminate the Company's Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study's Interim Analysis Data Monitoring Committee (the "IA-DMC" . While the results showed overall improvement in patients treated with the Company's proprietary cells, the magnitude of the effect and the perceived trend of the effect over time did not justify continuing the study or exploring the variability in the initial patient observations, given the financial resources available to the Company. STEM: 1.54 (unch)
StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study
GlobeNewswire - Tue May 10, 9:00AM CDT
StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway(TM) Study later this month as part of the Company's first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June.
STEM: 1.54 (unch)
StemCells, Inc. Announces 1-for-12 Reverse Stock Split
GlobeNewswire - Fri May 06, 11:49AM CDT
StemCells, Inc. (NASDAQ:STEM), announced today that at its annual stockholders meeting held on May 5, 2016, the Company's stockholders voted to approve a reverse stock split of the Company's common stock at a ratio of 1-for-12. Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Monday, May 9, 2016, under the existing trading symbol "STEM" and a new CUSIP number 85857R 303.
STEM: 1.54 (unch)
StemCells, Inc. (NASDAQ: STEM) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 6:45AM CDT
PALO ALTO, CA / ACCESSWIRE / May 3, 2016 / StemCells, Inc. (NASDAQ: STEM) a company engaged in the research, development, and commercialization of stem cell therapeutics, recently announced that management will make a presentation on the Company's programs, pipeline and operations at the 3rd Annual Growth Capital Expo MicroCap Investor Conference, held May 3 - 5, 2016 at Caesars Palace in Las Vegas, NV. The Company will be presenting at 11:00 a.m. Pacific Daylight Time on Wednesday, May 4. A live webcast of the presentation will be available through the Company's corporate website: http://www.stemcellsinc.com. Interested parties are encouraged to connect to the website at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary.
STEM: 1.54 (unch)
StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV
GlobeNewswire - Wed Apr 27, 7:05AM CDT
StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 3rd Annual Growth Capital Expo MicroCap Investor Conference, held May 3 - 5, 2016 at Caesars Palace in Las Vegas, NV. The Company will be presenting at 11:00 a.m. Pacific Daylight Time on Wednesday, May 4.
STEM: 1.54 (unch)
Top Penny Stocks: Four Trending Small Cap Stocks That Require Your Attention on April 18th 2016
ACCESSWIRE - Mon Apr 18, 10:17AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. SKLN, STEM, CYTX, and TRTC have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
SKLN: 0.18 (+0.02), CYTX: 2.05 (unch), STEM: 1.54 (unch)
StemCells, Inc. Presents Interim Results from its Phase II Pathway Study in Chronic Cervical Spinal Cord Injury at ASIA Annual Meeting
GlobeNewswire - Mon Apr 18, 7:05AM CDT
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, announced today that Dr. Stephen Huhn, the Company's Chief Medical Officer and VP of Clinical Research, presented additional details on its ongoing Phase II Pathway(TM) Study of HuCNS-SC cells for the treatment of chronic cervical spinal cord injuries. The presentation, which took place at the 2016 American Spinal Injury Association (ASIA) annual meeting in Philadelphia on Friday, April 15, included a top line update for the six patients enrolled in open label Cohort I from the Pathway Study. The 6-month results from Cohort I showed that muscle strength had improved in five of the six patients with four of these five patients also demonstrating improved performance on functional tasks assessing dexterity and fine motor skills. In addition, four of the six patients had improvement in the level of cord injury as measured by ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) assessment. The Company expects to release detailed final 12-month results on this first open-label cohort later this quarter.
STEM: 1.54 (unch)
StemCells, Inc., Pathway(TM) Study in Cervical Spinal Cord Injury Featured in The Downey Patriot
GlobeNewswire - Wed Mar 30, 3:13PM CDT
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced the company's ongoing Phase II Pathway(TM) Study in cervical spinal cord injury (SCI) was featured in an article published in The Downey Patriot.
STEM: 1.54 (unch)
Ian Massey, President and CEO of StemCells, Inc., to Participate on a Regenerative Medicine Panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Feb 04, 3:07PM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Ian Massey, President and CEO of StemCells, Inc., will participate on a regenerative medicine panel at Source Capital Group's 2016 Disruptive Growth and Healthcare Conference. The panel will take place on Feb. 10, at 1:30 p.m., Eastern Standard Time, at the Convene Conference Center, 730 3 Avenue, in New York City. The panel will be moderated by Todd Fromer, principal of KCSA Strategic Communications. Other panel members will include Adi Mohanty, Co-CEO, BioTime, Karine Kleinhaus, Div. VP, N.A., Pluristem Therapeutics, Dan Goldberger, CEO, Xtant Medical, and Mark Hedrick, MD, CEO, Cytori Therapeutics.
PSTI: 1.65 (+0.01), STEM: 1.54 (unch)
Endonovo Therapeutics Tops Our List For Investor Potential in Biotechs
ACCESSWIRE - Thu Jan 28, 11:11AM CST
LAS VEGAS, NV / ACCESSWIRE / January 28, 2016 / Now that investors have gotten their first taste of the potential returns from the treatment of liver diseases, such as hepatitis C, which generated over $12.5 billion in 2014 sales and another $14.3 billion in the first nine months of 2015 for Gilead, companies are now looking to target other large liver disease markets.
INO: 9.08 (-0.06), PSTI: 1.65 (+0.01), GERN: 2.75 (+0.02), STEM: 1.54 (unch)
CORRECTING and REPLACING -- StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Jan 28, 10:15AM CST
In a release issued under the same headline earlier today by StemCells, Inc. (Nasdaq:STEM), please note that in the third paragraph of the release, the 2016 Disruptive Growth and Healthcare Conference date should be Feb. 10, not Feb. 18 as previously stated. The corrected release follows:
STEM: 1.54 (unch)
StemCells, Inc. to Participate at the 2016 BIO CEO Conference and Source Capital Group's 2016 Disruptive Growth and Healthcare Conference
GlobeNewswire - Thu Jan 28, 7:05AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that management will make presentations on the Company's programs, pipeline and operations at two upcoming conferences in February.
STEM: 1.54 (unch)
3 Stocks Tackling Concussion Issues in Pro Athletes
ACCESSWIRE - Wed Jan 20, 7:45AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / The 2015 drama Concussion starring Will Smith follows the story of Dr. Bennet Omalu's battle with the National Football League to acknowledge research on the brain damage suffered by professional football players. After examining the brains of many deceased NFL players, Dr. Omalu coined the term chronic traumatic encephalopathy (CTE) to represent the large accumulation of tau protein on the brain causing a wide range of mental problems.
STEM: 1.54 (unch), CEMI: 7.22 (+0.05), CUR: 0.25 (-0.02)
StemCells, Inc. CEO Martin McGlynn Passes Baton to President and COO Ian Massey
GlobeNewswire - Mon Jan 11, 7:05AM CST
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, today announced that Dr. Ian Massey, its President and Chief Operating Officer, has been appointed by the Board of Directors to succeed Martin McGlynn as the Company's Chief Executive Officer, effective January 18, 2016. Massey has additionally been elected to the Board.
STEM: 1.54 (unch)
StemCells, Inc. to Participate at the 8th Annual Biotech Showcase Investor Conference
GlobeNewswire - Wed Jan 06, 7:05AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 8 Annual Biotech Showcase Investor Conference. Management is scheduled to speak at 4:30 p.m. Pacific Standard Time on Monday, January 11, at the Parc 55 Hotel, located at 55 Cyril Magnin Street, San Francisco.
STEM: 1.54 (unch)
StemCells, Inc. Announces Strategic Realignment
GlobeNewswire - Wed Dec 23, 7:05AM CST
StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced a strategic realignment to fully focus the Company's resources on its proprietary HuCNS-SC platform technology for the treatment of chronic spinal cord injury (SCI).
STEM: 1.54 (unch)
Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Tue Dec 08, 8:02AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird"
in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives. STEM: 1.54 (unch)
(0)
(0)Scroll down for more posts ▼